How tiny particles from brain cells may trigger the immune system in Alzheimer’s
Official title: CNS Exosomes-Mediated Adaptive Immunity in Alzheimer's Disease (AD)
Funded at Tufts University Boston · NIH-11103395 · Data updated 2026-11-12
This project looks at whether small vesicles released by brain cells carry Alzheimer’s-related signals that activate the immune system in people with Alzheimer’s disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $816,608 |
| NIH project number | 5R01AG078728-04 |
| Project ID | NIH-11103395 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with Alzheimer’s disease or mild cognitive impairment and their caregivers who follow advances in immune and biomarker research would be the most relevant audience for these findings.
✕Less likely to help
People without Alzheimer’s or those whose conditions are driven by non-neurological causes are unlikely to gain direct benefit from this basic science project.
What this research studies
Researchers are testing whether brain-derived exosomes (small extracellular vesicles) carry Alzheimer’s-specific proteins that can stimulate T or B cells and drive immune responses. They will use genetically labeled mouse models that let scientists trace exosomes from specific brain cell types and follow where those exosomes travel in the body. The team will analyze the exosome contents and measure immune activation in peripheral organs to see if brain antigens reach and engage adaptive immune cells. Findings may point to new blood or immune markers and help explain how brain pathology interacts with the immune system in Alzheimer’s.
Why it matters
Potential benefit: If successful, this work could identify new immune-related biomarkers or targets that help guide future immune-based therapies for Alzheimer’s disease.
How similar studies have gone: Prior studies have linked innate immune cells and exosomes to Alzheimer’s, but showing that brain-derived exosomes trigger adaptive (T/B cell) responses is a newer and only partially explored idea.
Where this research is happening
-
Tufts University Boston
Boston, United States Active
Researchers
- Principal investigator: Yang, Yongjie — Tufts University Boston
- Study coordinator: Yang, Yongjie
Related research
Other NIH-funded projects on the same topics.
-
Alzheimer’s disease and related brain changes linked to chemicals in the body
This NIH grant supports a patient-centered effort to map how environmental exposures and body chemistry relate to Alzheimer’s disease and related dementias.
-
Understanding how everyday exposures affect Alzheimer's disease progression
A national research effort is studying how environmental exposures, gut health, diet, and metabolism relate to Alzheimer's and related dementias to identify new ways to diagnose and treat these conditions.
-
How environment, gut health, and metabolism affect Alzheimer’s disease
This grant looks at how environmental exposures, gut microbes, diet, and metabolism influence Alzheimer’s disease and related dementias.
-
Understanding how chemical exposures affect Alzheimer's disease progression
This project studies how environmental chemicals and other biological factors influence brain health and the course of Alzheimer’s disease and related dementias.
-
Understanding how brain hyperexcitability and sex differences affect Alzheimer’s disease
This grant tests whether brain hyperexcitability linked to a genetic risk (APOE4) and sex differences contribute to memory decline in Alzheimer’s disease, using computer simulations and mouse data to guide potential human treatments.
-
CNS Exosomes and Adaptive Immunity in Alzheimer’s Disease
This project studies how tiny brain vesicles called exosomes may activate the body's immune system in Alzheimer’s disease, with the goal of understanding mechanisms that could lead to new treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.